Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study

• by Chu Fan, Hangyu Yan, Kehang Lei, Dan Li, Shutong Dong, Yue Zhang, Cecily Patricia Callister, Yutong Cheng, Zhao Li, Zhizhong Li, Haiyan Qian, Ji Huang

• December 30, 2025

Tricuspid regurgitation thresholds reassessed

The proposed framework classified 30% of patients as high or extreme risk, compared with 12% classified as having severe or greater tricuspid regurgitation under established grading schemes.

• by Kathryn Wighton

• September 9, 2026

• 4 min

Disparities in the management of cardiogenic shock complicating acute myocardial infarction: a questionnaire survey in Beijing

• by Yidan Ren, Yuwei Liu, Yaxin Xie, Chenxu Zhao, Xiaqiu Tian, Liangshan Wang, Zhongtao Du, Xing Hao, Chenglong Li, Xiaotong Hou, Hong Wang

• September 25, 2026

Circulating Dipeptidyl Peptidase 3 levels, an Antagonist of Angiotensin-(1–7), in Acute Heart Failure: Insights from the PUSH-AHF trial

• by Stijn Legtenberg, Karine Santos, Iris E. Beldhuis, Oliver Hartmann, Lara E.E.C. Zonneveld, Peter van der Meer, Jan A. Krikken, Wybe Nieuwland, Dirk J. van Veldhuisen, Adriaan A. Voors, Kevin Damman, Jozine M. ter Maaten

• September 4, 2026